Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on advancing disruptive solutions aimed at improving patient experiences and outcomes for both emerging and established therapies. The company has developed the ENHANZE® drug delivery technology, leveraging the proprietary enzyme rHuPH20 to facilitate the subcutaneous delivery of injected drugs and fluids, enhancing the patient experience with rapid…
OverT Bio, an NYCbased cell therapy company, has been awarded a $120,000 GRex Grant from ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, BioTechne Corporation (NASDAQ: TECH), and CellReadyTM. This funding will support OverT Bios development of nextgeneration cell therapies for solid tumors, utilizing innovative datadriven discovery platforms OverTargetTM and OverTCRTM. “We are pleased to receive…
The Children’s Inn at the National Institutes of Health (NIH) has been awarded a significant $1 million grant from Gilead Sciences Inc. to support its renovation and expansion efforts. This funding will contribute to the creation of The Gilead Sciences Welcome Center, a key part of The Inn of Tomorrow, a substantial $50plus million project…
Pep2Tango Therapeutics Inc. is a biotechnology startup founded in 2021 by experienced pharmaceutical executives. The company is focused on creating innovative, nextgeneration weight loss therapies. Their lead drug candidates are unimolecular multireceptor peptide agonists that target GLP1, GIP, amylin, and calcitonin receptors. This approach aims to provide superior weight loss efficacy while preserving muscle mass…
Debiopharm, a Swissbased global biopharmaceutical company, has received an extension of funding from CARBX, a global nonprofit partnership committed to supporting earlystage antibacterial research and development. The $5.76 million USD grant will aid in the preclinical development of Debio 1453, an innovative antibiotic targeting Neisseria gonorrhoeae infections. The funding is pivotal for the completion of…
Enveda, a biotechnology company utilizing AI to transform natural compounds into novel medicines, has successfully closed an oversubscribed $130 million Series C funding round. The funding was led by Kinnevik and FPV, with participation from new and existing investors including Baillie Gifford, Premji Invest, Lingotto Innovation, Lux Capital, Dimension Capital, True Ventures, Cresset Partners, The…
OncoVerity, a pioneer in applying advanced bioinformatics to drug development, announced the closing of a Series A extension financing led by existing investors, argenx and RefinedScience. The proceeds from this funding round will be used to advance the Phase 2 OVAML1231 trial of cusatuzumab, a novel, firstinclass highaffinity monoclonal antiCD70 antibody. This trial is aimed…
Company Description: Glox Therapeutics is pioneering the development of precision antibiotic therapies using naturally occurring bacteriocins. The company focuses on creating a new class of antimicrobials that target specific drugresistant pathogens, such as Escherichia coli and Klebsiella pneumoniae, without harming the human microbiome. Funding Usage: The £1 million grant from PACE will accelerate the development…
Valora Therapeutics Inc. is a biotechnology company pioneering a novel approach to immunotherapy. The funding will be used to advance Valoras proprietary AbLec platform, which focuses on developing novel immunotherapeutics by targeting specific sugar molecules on cells, modulating glycoimmune checkpoints. These efforts are directed toward developing firstinclass and bestinclass therapeutics in oncology, autoimmune diseases, and…
Description about the company receiving the funding: Alchemyca is a company that utilizes enzymes, sensors, and AI to improve the conversion of organic waste into renewable natural gas. They focus on enhancing the efficiency of biogas production, aiming to make organic waste a viable, lowcost feedstock for versatile chemicals and fuels. Led by renewable energy…